Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Vivani Medical (Nasdaq:VANI) today announced steps enabling it to focus solely on its GLP-1-delivering implant technologies.

From going blind and suffering from life-long diarrhea to battling addiction and finding love, people who take Ozempic and other GLP-1 medications are seeing that the drugs are doing more than ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

In an increasingly competitive telehealth weight loss market, thoughtful and transparent branding is critical.

Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...